Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Outlook Therapeutics (OTLK) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to -$8.7 million.

  • Outlook Therapeutics' Enterprise Value fell 5216.67% to -$8.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$8.7 million, marking a year-over-year decrease of 5216.67%. This contributed to the annual value of -$8.1 million for FY2025, which is N/A changed from last year.
  • As of Q4 2025, Outlook Therapeutics' Enterprise Value stood at -$8.7 million, which was down 5216.67% from -$8.1 million recorded in Q3 2025.
  • In the past 5 years, Outlook Therapeutics' Enterprise Value ranged from a high of -$5.7 million in Q4 2024 and a low of -$8.9 million during Q2 2025